4DMT to Participate in Upcoming Investor Conferences
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage company specializing in genetic medicines for large market diseases, has announced its participation in two major investor conferences in March 2025.
The company will engage in fireside chats at Leerink's Global Biopharma Conference on Tuesday, March 11, 2025, at 10:00 a.m. ET, and at the Barclays Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET. Management team members will be available for one-on-one meetings during both events.
Webcasts of both presentations will be accessible through the company's website, with archived versions remaining available for up to one year in the 'Investors' section at ir.4dmoleculartherapeutics.com/events.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, FDMT declined 2.47%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.
Leerink's Global Biopharma Conference 2025
Presentation Date: Tuesday, March 11, 2025
Presentation Time: 10:00 a.m. ET
Webcast Link: Webcast
Barclays Global Healthcare Conference 2025
Presentation Date: Wednesday, March 12, 2025
Presentation Time: 10:00 a.m. ET
Webcast Link: Webcast
Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When will 4DMT (FDMT) present at Leerink's Global Biopharma Conference 2025?
What is the schedule for FDMT's presentation at the Barclays Global Healthcare Conference 2025?
How long will the webcasts of FDMT's March 2025 investor conferences be available?
Where can investors access FDMT's March 2025 conference presentations?
Will FDMT management be available for individual meetings during the March 2025 conferences?
